GENEVA, Switzerland- The World Health Organization has issued its first guidelines on the diagnosis and management of type 1 diabetes in adults, calling for reliable access to insulin, regular blood-glucose monitoring and care that can work even in low-resource, emergency and humanitarian settings.
The guidance was released to mark World Diabetes Day 2026, as WHO warned that many people with type 1 diabetes still cannot access the insulin and monitoring supplies they need to survive.
Type 1 diabetes is a lifelong condition in which the body produces too little or no insulin, meaning people require daily insulin treatment.
WHO estimates that about 9.5 million people were living with type 1 diabetes globally in 2025, with a further 500,000 people diagnosed during the year.
While it is often associated with children, WHO says the condition is increasingly affecting adults.
Multiple daily insulin doses recommended
The new guideline strongly recommends intensified insulin treatment using multiple daily injections, with doses adjusted according to blood-glucose readings.
WHO says human insulin is an appropriate and effective option and is generally preferred because it is usually less expensive.
Insulin analogues can also be used where needed and where they are available.
The recommendations are intended to help health workers, policymakers, programme managers and humanitarian organisations deliver safe and practical care across different settings.
“The new WHO guidelines provide evidence-based recommendations to help countries deliver the best possible care, including in settings where resources are limited and health services are disrupted,” said Dr Søren Brostrøm, WHO’s Director of Noncommunicable Diseases and Mental Health.
Monitoring remains central to care
WHO recommends regular monitoring of blood-glucose levels to help people and their healthcare providers adjust treatment safely.
At health facilities, this can include tests that show average blood-sugar control over the preceding months.
At home, people may monitor their glucose using finger-prick tests or continuous glucose monitors, which use small sensors worn on the skin.
Where blood-glucose testing is not available, the guideline says urine-glucose testing can be considered as an alternative.
The WHO says the recommendations aim to support its 2030 target of ensuring that all people living with type 1 diabetes can access affordable insulin and blood-glucose self-monitoring.
Focus on early action and access
The 2026 World Diabetes Day theme is “Early action on diabetes”, highlighting the importance of earlier diagnosis, timely treatment and reducing stigma.
WHO warns that untreated or poorly managed diabetes can lead to serious health complications, including blindness, kidney failure, heart attacks, stroke and lower-limb amputation.
The wider global burden of diabetes has more than quadrupled since 1990. In 2022, about 830 million people were living with diabetes worldwide, most of them with type 2 diabetes.
WHO estimates that more than 40% of people with diabetes remain undiagnosed.
The organisation says people should seek medical advice if they experience symptoms such as increased thirst, frequent urination, unexplained weight loss, tiredness or blurred vision.
Type 1 diabetes can develop rapidly and may be missed or misdiagnosed in adults.
WHO says countries should involve people living with type 1 diabetes in designing and evaluating diabetes programmes, alongside efforts to improve medicine supply chains, strengthen primary healthcare and expand access to monitoring technologies.
The guidance is primarily for health professionals and health-system planners.
People living with diabetes should not change their insulin dose or treatment plan based on a news report and should consult a qualified healthcare provider for personalised advice.




